ABSTRACT
INTRODUCTION
Resistance to active drugs such as platinum compounds commonly occurs during treatment of EOC (1, 2) . These drugs form electrophilic intermediates that act via nucleophilic substitution reactions to form inter-and intrastrand DNA crosslinks. The cellular response to electrophilic xenobiotics is partly mediated by the Keap1-Nrf2 signaling system (3). Nrf2 (NF-E2-Related Factor 2) is a leucine zipper transcription factor, which under basal conditions is tethered to its cytoplasmic inhibitor Keap1 (Kelch-like ECH-Associated Protein 1). Upon binding to Nrf2, Keap1 inhibits Nrf2 function by promoting degradation of Nrf2 (4) .
Electrophilic xenobiotics trigger the disassociation of Nrf2 from Keap1, allowing subsequent translocation of Nrf2 into the nucleus. Nrf2 subsequently activates transcription of a variety of genes whose protein products protect against oxidative stress, mediate detoxification of substances through glutathione conjugation, and participate in ATP-dependent drug efflux (5, 6) .
The role that the Keap1-Nrf2 pathway plays in the development of drug resistance in EOC is poorly understood. In this study, we assessed the prevalence of Keap1 mutations and Nrf2 pathway activation in EOC, and the relationship between Nrf2 pathway activation, platinum resistance, and clinical outcome. 
MATERIALS AND METHODS

Patient samples and cell culture
Formalin-fixed, paraffin embedded tissue from 30 EOC patients treated at Beth Israel Deaconess Medical Center (BIDMC) were included in this study (Supplementary Table 1 ). The study protocol for collection of tissue and clinical information was approved by the institutional review board at BIDMC. The 36M2 human EOC cell line was derived from serial passage of ovarian serous carcinoma cells in nude mice as previously described (7) .
Immunohistochemistry
Immunohistochemistry to detect nuclear expression of Nrf2 was determined as described in Supplementary Methods.
Cases displaying nuclear Nrf2 immunostaining in more than 10% of tumor cells were regarded as positive.
Real-Time PCR
Total RNA was isolated from 36M2 cells using RNeasy Mini Kit (Qiagen).
Reverse transcription was done with 1 ȝg starting total RNA and the Promega Reverse Transcription System (Promega) according to the manufacturer's instructions. SYBR Green I-based real-time PCR was carried out on a MJ
Research DNA Engine Opticon Continuous Fluorescence Detection System. DNA was isolated from formalin fixed cancer tissue specimens using QIAamp DNA FFPE Tissue Kit (Qiagen). All protein-coding exons and intron-exon boundaries of the Keap1 and Nrf2 gene were amplified and sequenced using a two step "boost/nest" PCR strategy.
Bidirectional DNA sequencing was performed, and the sequences of all the primers (boost and nest primers) are provided in Supplementary Table 2 for both Keap1 and Nrf2. All reported sequence alterations were confirmed by sequencing in both directions and the associated base call accuracy was more than 99% in all cases.
Microarray Datasets and Analysis
Two publicly available microarray datasets were used in this study and have been previously described by our group and others (8, 9) . Hierarchical clustering based on the expression of Nrf2 pathway genes (i.e. genes of the Biocarta Nrf2 pathway including the experimentally validated Nrf2 target genes SOD2, GPX3, SLC3A1, GGT1, GSTM3, CRYZ, POR and NQO1) was performed using the average linkage method. Pathway analysis was performed using the EfronTibshirani's Gene Set Analysis method (10) . We also searched MsigDB datasets and the KEGG pathway database and identified one more signature (besides the Biocarta "NRF2 pathway") that included NRF2 genes termed "SINGH-NFE2L2-TARGETS". Inclusion of the "SINGH-NFE2L2-TARGETS" genes in pathway analyses and hierarchical clustering did not alter the results. Therefore, data are reported using only the genes of the Biocarta Nrf2 pathway and NQO1. 
Statistical Analysis
The association between Nrf2 immunohistochemistry results and various clinicopathological factors was assessed by Fisher's exact test. Overall survival (OS) curves were generated by the Kaplan-Meier method, and statistical significance was assessed using the log-rank test. Multivariate analysis was 
RESULTS
Nrf2 pathway activation in EOC
We performed immunohistochemistry (IHC) to assess the expression and localization of Nrf2 protein in 30 EOC specimens obtained during primary debulking surgery, with the results shown in Table 1 . Nuclear Nrf2 staining was detected in 17 (57%) of EOC specimens overall and was more common in clear cell EOCs (11 out of 14, 79%) compared to non-clear cell EOC (6 out of 16, 38%, two-sided Fisher's exact p = 0.033) (Table 1, Figure 1A -C). There were no differences in age, grade, or debulking status between Nrf2 immunopositive and negative specimens (Table 1) . Two normal mullerian epithelium specimens showed no evidence for Nrf2 nuclear protein by IHC ( Figure 1B ).
In order to evaluate whether presence of nuclear Nrf2 staining was associated with Nrf2 transcriptional activity, we compared the expression levels of two Nrf2 target genes (SOD2 and GPX3) in Nrf2 immunopositive and immunonegative specimens using quantitative real-time PCR. We found that both genes were statistically significantly upregulated in Nrf2 immunopositive compared to immunonegative specimens (16.3-and 13.8-fold for SOD2 and GPX3 respectively, p<0.05 for both genes, Figure 2A ). Furthermore, we found that both SOD2 and GPX3 were statistically significantly upregulated in clear cell Table 2 summarizes the Keap1 expression data, and the Keap1 and Nrf2 sequencing data in the Nrf2 immunopositive tumors.
As shown in Table 2 
Activation of the Nrf2 pathway via siRNA knockdown of Keap1
We assessed the effect of siRNA knockdown of Keap1, the cytoplasmic inhibitor of Nrf2, on the sensitivity of 36M2 ovarian cancer cells to carboplatin. SiRNA 
Correlation of Keap1-Nrf2 pathway with platinum responsiveness and clinical outcome
We used our publicly available ovarian cancer microarray dataset comprised of 64 advanced disease patients with EOC to investigate whether there was a relationship between Nrf2 pathway activation, platinum resistance, and overall survival (9) . Hierarchical clustering based on the expression levels of the Nrf2 pathway genes revealed two clusters/groups of patients ( Figure 5A ). The Nrf2 pathway was upregulated (Efron-Tibshirani's GSA test p < 0.005) in the first group ("Nrf2-pathway-up") compared to the second group ("Nrf2-pathway-down") of patients (heat map is shown in Supplement Figure 2 ). The majority of clear cell EOCs (4 out of 5, 80%) clustered in the "Nrf2-pathway-up" group and 1 clustered in the "Nrf2-pathway-down" group.
Patients in the Nrf2-pathway-up group had a lower complete clinical response rate to platinum, compared with patients in the Nrf2-pathway-down group (77% versus 97% respectively, two-sided Fisher's exact p = 0.015), ( Figure 5B).
Furthermore, 42% of patients in the Nrf2-pathway-up group were platinum resistant, compared to 16% of patients in the Nrf2-pathway-down group (twosided Fisher's exact p = 0.02), ( Figure 5B ). Finally, patients in the Nrf2-pathwayup group had inferior overall survival compared to patients in the Nrf2-pathwaydown group (34 months vs not-yet reached respectively, log rank p=0.031, Figure   5C ). In multivariable analysis adjusted for known prognostic factors, the hazard functional relationship between Nrf2 pathway activation and platinum resistance in the 36M2 ovarian cancer cell line. Nrf2 pathway was induced via siRNA knockdown of its cytoplasmic inhibitor Keap1 (Figure 4A ), leading to enhanced the transcriptional activity of Nrf2 and rendering 36M2 cells more resistant to carboplatin ( Figure 4B ).
Keap1 mutations have been reported in some patients with non small cell lung cancer (13) (11), small cell lung cancer (11) and biliary tract cancer (12) . One study also reported that the human Q293 breast cancer cell line harbors a Keap1 mutation that encodes an inactive Keap1 protein (19) . The majority of these Keap1 mutations in cancer patients were heterozygous. In our study, we CAN-10-4668 16). Based on the recently proposed two-site substrate recognition model for Keap1-Nrf2 interaction, formation of an homodimer of two normal Keap1 subunits that associates with two sites of Nrf2 is necessary for ubiquitination and eventual degradation of Nrf2 (20) . In this regard, it has been reported that in tumors that are heterozygous for Keap1 mutations, the heterodimer between a wild-type Keap1 subunit and a mutant Keap1 subunit is inactive and unable to repress Nrf2 function (11) . Finally, there was one missense mutation in 1 papillary serous tumor, which contained only the mutant G-C allele, associated with a highly conserved amino acid change in the BTB domain ( Figure 3 and Supplement Table 3 ).
We also evaluated whether other mechanisms (besides Keap1 mutations) may be associated with Nrf2 pathway activation in EOC.
In this regard, Given the presence of Nrf2 pathway activation in at least some patients with EOC, and the observation that activation of Nrf2 pathway increases platinum resistance in 36M2 ovarian cancer cells, we investigated whether this pathway is associated with clinical outcome in ovarian cancer using a publicly available gene expression dataset of 64 patients with advanced EOC. Patients with upregulated Nrf2 pathway had a lower CCR rate after 1st line therapy, and they were enriched for platinum resistance. Furthermore, activation of Nrf2 pathway was associated with worse overall survival independent of standard prognostic factors such as age, grade, histology, stage, and debulking status (Supplement Table 4 ).
Because the majority of the 64 patients had papillary serous tumors, these findings suggest that activation of the Nrf2 pathway may correlate with platinum resistance not only in clear cell EOC but also in other histologies.
In conclusion, the Nrf2 pathway is activated at baseline in some patients with 
